Tarcocimab tedromer
As of the edition of 20 October 2026, Tarcocimab tedromer is an antibody drug conjugate: stopped in 2023; acts on VEGFA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Antibody drug conjugate
- Registered trials
- 8, 5 stopped early
- Disease areas
- Eye; Nervous system; Heart and blood vessels; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Tarcocimab tedromer.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | P15692 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 3 | 7 | 2 | 1 | 4 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Kodiak Sciences | Lead sponsor of trials | 2018 to now |